~~<i id='563523F5CD'><strike id='563523F5CD'><tt id='563523F5CD'><pre id='563523F5CD'></pre></tt></strike></i>~~

Home» leisure time» focus

focus

author：knowledge 2025-10-02 04:24:22 Page View：232

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Buoyed by wins on obesity, Novo Nordisk eyes heart disease
Next article： Alkermes shareholders re

focus

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

Timeline: Special counsel's investigation into Trump's handling of classified documents

7:06ThisimagecontainedinacourtfilingbytheDepartmentofJusticeonAug.30,2022,andpartiallyredactedbythes

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

CDC overhauls leadership of center that led response to Covid

DemetreDaskalakis,whohasspentthepastyearinWashingtonasdeputydirectoroftheWhiteHouse’smpoxresponse,wa

WSS

focus

focus

comprehensive

focus

CDC overhauls leadership of center that led response to Covid